Curasight
HC Andersen Capital receives payment from Curasight for a DigitalIR/Corporate Visibility agreement. See disclaimer.
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreLatest research
Analyst
Curasight: Directed issues registered at the Danish Business Authority
Curasight: Management remains confident on its strategy as new financing plan is launched
Join Inderes community
Don't miss out - create an account and get all the possible benefits